{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:24:53Z","timestamp":1793874293213,"version":"4.6.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bbagen.2026.131001","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:24:14Z","timestamp":1789086254000},"page":"131001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting skeletal muscle wasting: emerging therapeutics and translational challenges"],"prefix":"10.1016","volume":"1870","author":[{"given":"Brandon M.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0005","first-page":"213","article-title":"Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia: overlap of clinical features","volume":"15","author":"Jeejeebhoy","year":"2012","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0010","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1152\/physrev.00061.2017","article-title":"Sarcopenia: aging-related loss of muscle mass and function","volume":"99","author":"Larsson","year":"2019","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.bbagen.2026.131001_bb0015","first-page":"C1068","article-title":"Disuse-induced skeletal muscle atrophy in disease and nondisease states in humans: mechanisms, prevention, and recovery strategies","volume":"322","author":"Nunes","year":"2022","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"2 Suppl","key":"10.1016\/j.bbagen.2026.131001_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.afos.2025.05.004","article-title":"Definition and diagnosis of sarcopenia: Asia-Pacific perspectives","volume":"11","author":"Huang","year":"2025","journal-title":"Osteoporos. Sarcopenia"},{"issue":"4","key":"10.1016\/j.bbagen.2026.131001_bb0025","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ageing\/afz046","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"5","key":"10.1016\/j.bbagen.2026.131001_bb0030","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/jcsm.13323","article-title":"Diagnosis and outcomes of cachexia in Asia: working consensus report from the Asian working group for cachexia","volume":"14","author":"Arai","year":"2023","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40520-024-02798-4","article-title":"An executive summary on the global conceptual definition of sarcopenia","volume":"36","author":"Kirk","year":"2024","journal-title":"Aging Clin. Exp. Res."},{"issue":"5","key":"10.1016\/j.bbagen.2026.131001_bb0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bbagen.2026.131001_bb0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jshs.2023.04.001","article-title":"Skeletal muscle atrophy, regeneration, and dysfunction in heart failure: impact of exercise training","volume":"12","author":"Gallagher","year":"2023","journal-title":"J. Sport Health Sci."},{"key":"10.1016\/j.bbagen.2026.131001_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155639","article-title":"Sarcopenic obesity: emerging mechanisms and therapeutic potential","volume":"146","author":"Axelrod","year":"2023","journal-title":"Metabolism"},{"issue":"Suppl. 1","key":"10.1016\/j.bbagen.2026.131001_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/gerona\/glad033","article-title":"Challenges and future prospects of targeting myostatin\/activin a signaling to treat diseases of muscle loss and metabolic dysfunction","volume":"78","author":"Lee","year":"2023","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0060","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1038\/s41467-025-59485-9","article-title":"GDF8 and activin a blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates","volume":"16","author":"Mastaitis","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0065","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/s41467-022-32135-0","article-title":"Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer","volume":"13","author":"Queiroz","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagen.2026.131001_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol Metab"},{"issue":"6731","key":"10.1016\/j.bbagen.2026.131001_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.adi4736","article-title":"Muscle-derived myostatin is a major endocrine driver of follicle-stimulating hormone synthesis","volume":"387","author":"Ongaro","year":"2025","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bbagen.2026.131001_bb0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"issue":"16","key":"10.1016\/j.bbagen.2026.131001_bb0085","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1074\/jbc.RA119.012293","article-title":"Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015","volume":"295","author":"Dagbay","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0090","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-026-04204-0","article-title":"Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial","volume":"32","author":"Heymsfield","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagen.2026.131001_bb0095","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000001113","article-title":"Bimagrumab: novel medical therapy for inclusion body myositis, sarcopenia, and medication-induced lean body mass loss","author":"Kaiser","year":"2025","journal-title":"Cardiol. Rev."},{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1164\/rccm.201802-0286OC","article-title":"Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. A randomized trial","volume":"199","author":"Polkey","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0105","article-title":"Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: the phase 2 TOPAZ study","volume":"103","year":"2024","journal-title":"Neurology"},{"issue":"49","key":"10.1016\/j.bbagen.2026.131001_bb0110","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1073\/pnas.2019263117","article-title":"Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A","volume":"117","author":"Lee","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbagen.2026.131001_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.mce.2017.06.013","article-title":"Development of selective androgen receptor modulators (SARMs)","volume":"465","author":"Narayanan","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"issue":"12","key":"10.1016\/j.bbagen.2026.131001_bb0120","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1021\/jm900280m","article-title":"Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit","volume":"52","author":"Mohler","year":"2009","journal-title":"J. Med. Chem."},{"issue":"39","key":"10.1016\/j.bbagen.2026.131001_bb0125","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2407768121","article-title":"The androgen receptor in mesenchymal progenitors regulates skeletal muscle mass via Igf1 expression in male mice","volume":"121","author":"Sakai","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.bbagen.2026.131001_bb0130","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1210\/en.2015-1479","article-title":"Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the androgen receptor in the satellite cell lineage","volume":"156","author":"Dubois","year":"2015","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.bbagen.2026.131001_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084404","article-title":"Ostarine-induced myogenic differentiation in C2C12, L6, and rat muscles","volume":"23","author":"Leciejewska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bbagen.2026.131001_bb0140","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/1440-1681.13824","article-title":"RAD140 (Testolone) negatively impacts skeletal muscle adaptation, frailty status and mortality risk in female mice","volume":"50","author":"Brown","year":"2023","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.bbagen.2026.131001_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2025.112054","article-title":"The impact of a selective androgen receptor modulator (RAD140) on frailty and underlying mechanisms in older male and female C57Bl\/6 mice","volume":"225","author":"Heinze","year":"2025","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.bbagen.2026.131001_bb0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.exger.2018.02.023","article-title":"Human neuromuscular aging: sex differences revealed at the myocellular level","volume":"106","author":"Roberts","year":"2018","journal-title":"Exp. Gerontol."},{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.bbagen.2026.131001_bb0160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bbagen.2026.131001_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","article-title":"Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials)","volume":"18","author":"Crawford","year":"2016","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/thorax-2021-218360","article-title":"Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial","volume":"78","author":"Mohan","year":"2023","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.bbagen.2026.131001_bb0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tem.2022.12.001","article-title":"Ghrelin receptor signaling in health and disease: a biased view","volume":"34","author":"Gross","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jcsm.12861","article-title":"Cannabinoid interventions for improving cachexia outcomes in cancer: a systematic review and meta-analysis","volume":"13","author":"Simon","year":"2022","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"12","key":"10.1016\/j.bbagen.2026.131001_bb0185","article-title":"Acylated ghrelin receptor agonist HM01 decreases lean body and muscle mass, but unacylated ghrelin protects against redox-dependent sarcopenia","volume":"11","author":"Ranjit","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"10.1016\/j.bbagen.2026.131001_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071942","article-title":"Supplementary Oral Anamorelin mitigates anorexia and skeletal muscle atrophy induced by gemcitabine plus cisplatin systemic chemotherapy in a mouse model","volume":"12","author":"Miyake","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bbagen.2026.131001_bb0195","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1111\/cas.15491","article-title":"Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model","volume":"113","author":"Hanada","year":"2022","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.bbagen.2026.131001_bb0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13732","article-title":"Anamorelin efficacy in non-small-cell lung cancer patients with cachexia: insights from ROMANA 1 and ROMANA 2","volume":"16","author":"Laird","year":"2025","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"9","key":"10.1016\/j.bbagen.2026.131001_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7170","article-title":"Real-world safety and effectiveness of anamorelin for cancer cachexia: interim analysis of post-marketing surveillance in Japan","volume":"13","author":"Takayama","year":"2024","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.bbagen.2026.131001_bb0215","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10120-025-01637-3","article-title":"Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study","volume":"28","author":"Yanagimoto","year":"2025","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0220","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12967-023-04369-z","article-title":"Mitochondrial dysfunction: roles in skeletal muscle atrophy","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26030944","article-title":"Elamipretide: a review of its structure, mechanism of action, and therapeutic potential","volume":"26","author":"Tung","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbagen.2026.131001_bb0230","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.freeradbiomed.2018.12.031","article-title":"Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice","volume":"134","author":"Campbell","year":"2019","journal-title":"Free Radic. Biol. Med."},{"issue":"6","key":"10.1016\/j.bbagen.2026.131001_bb0235","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1007\/s11357-023-00861-y","article-title":"The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT)","volume":"45","author":"Pharaoh","year":"2023","journal-title":"Geroscience"},{"issue":"2","key":"10.1016\/j.bbagen.2026.131001_bb0240","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ehf2.12408","article-title":"Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure","volume":"6","author":"Sabbah","year":"2019","journal-title":"ESC Heart Fail."},{"issue":"38","key":"10.1016\/j.bbagen.2026.131001_bb0245","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.18632\/oncotarget.27748","article-title":"Pharmacological targeting of mitochondrial function and reactive oxygen species production prevents colon 26 cancer-induced cardiorespiratory muscle weakness","volume":"11","author":"Smuder","year":"2020","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bbagen.2026.131001_bb0250","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcsm.12559","article-title":"A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy","volume":"11","author":"Karaa","year":"2020","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0255","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1212\/WNL.0000000000207402","article-title":"Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial","volume":"101","author":"Karaa","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13023-024-03421-5","article-title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial","volume":"19","author":"Karaa","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13841","article-title":"Sarcopenia in ageing and chronic illness: trial endpoints and regulatory issues","volume":"16","author":"von Haehling","year":"2025","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s40520-020-01663-4","article-title":"Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults","volume":"33","author":"Reginster","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"issue":"3","key":"10.1016\/j.bbagen.2026.131001_bb0275","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/jcsm.13453","article-title":"Quality of life endpoints in cancer cachexia clinical trials: systematic review 3 of the cachexia endpoints series","volume":"15","author":"Hjermstad","year":"2024","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0280","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1038\/s41467-025-59380-3","article-title":"GDF8 and activin a are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial","volume":"16","author":"Gonzalez Trotter","year":"2025","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bbagen.2026.131001_bb0285","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209151","article-title":"Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: the phase 2 TOPAZ study","volume":"102","author":"Crawford","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.bbagen.2026.131001_bb0290","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000409","article-title":"Drug-induced liver injury associated with alpha bolic (RAD-140) and alpha elite (RAD-140 and LGD-4033)","volume":"7","author":"Barbara","year":"2020","journal-title":"ACG Case Rep J"},{"issue":"1","key":"10.1016\/j.bbagen.2026.131001_bb0295","article-title":"Acute myocarditis from the use of selective androgen receptor modulator (SARM) RAD-140 (Testolone)","volume":"14","author":"Padappayil","year":"2022","journal-title":"Cureus"}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416526001017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416526001017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:28:06Z","timestamp":1793870886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416526001017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0304416526001017"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2026.131001","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting skeletal muscle wasting: emerging therapeutics and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2026.131001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"131001"}}